Vaccine Intelligence
Vaccine performance & coverage across seasons
VE trends, enhanced formulation compare (HD-QIV vs aQIV vs SD vs RIV4 vs Investigational Prophylactic), coverage vs HP2030 target.
VE 2025–26 (hosp)
27%
95% CI 21–34
HD rVE vs SD
42%
VE in IC
5%
Investigational Prophylactic target
76%
Season-long 24 wks
VE Trends 2016–2026
Overall VE vs age ≥65 VE with 60% HP2030 reference line
Traditional VE oscillates 16–54% by season. Mismatched years drop close to zero.
Coverage vs HP2030 target
Coverage by subgroup and season
Only long-stay nursing home residents exceed HP2030's 70% target. ≥65 sits just under.
Formulation Compare
Head-to-head rVE across enhanced vaccines and Investigational Prophylactic
HD-QIV vs SD
≥65 hosp
24.0%
(18–30)
HD-QIV vs SD
NH mortality
42.0%
(30–54)
aQIV vs SD
≥65 hosp
8.0%
(-2–17)
aQIV vs HD
≥65 hosp
3.1%
(-3–9)
RIV4 vs SD
Adults >50 outpatient
30.0%
(10–47)
Cell vs SD
Adults ≥18 outpatient
10.0%
(-5–22)
Investigational Prophylactic vs Placebo (P2b)
Symptomatic lab-conf
76.0%
(66–84)
Forest-plot-style effect estimates; violet dashed = Investigational Prophylactic target.